NEW YORK, Oct. 29, 2009 (GLOBE NEWSWIRE) -- KantarHealth is expanding its CardioMonitor service into Japan and China. A globally consistent cardiovascular and diabetes patient database, CardioMonitor will add 4,500 Japanese patients in December 2009 and 4,500 Chinese patients in February 2010. The new information will help pharmaceutical and biotech companies size opportunities, identify treatment dynamics, position products and sharpen forecasts in the growing Japanese and Chinese markets. Formed by uniting Consumer Health Sciences, MattsonJack, TNS Healthcare and Ziment, KantarHealth is the world's leading global healthcare consultancy, specializing in portfolio optimization, market access, safety and outcomes, and brand and customer insights.
Based on patient diaries collected online, CardioMonitor delivers insights into all major cardiovascular disease states and related risk areas, including hypertension, dyslipidemia, atrial fibrillation and type-2 diabetes. Because it uses the same methodology in the US, Europe and Asia, it provides consistent views across all target markets, with detailed information on patient demographics, diagnoses, test results, risk factors, co-morbidities, BMI and waist measurements. It also reveals prescribing dynamics, as well as the reasons driving physicians' treatment decisions.
"As the Asian markets become increasingly critical to our clients' business success, we wanted to ensure they had the information they need to optimize their brand performance in these high-potential countries," says Christine Brignall, Senior Director, Global Syndicated Studies for KantarHealth. "Consider that the pharmaceutical industry in China is growing by 25% annually, healthcare expenditures in China have more than doubled in just the last 5 years, and the over 65 population is expected to increase 300% in many Asian markets by 2025, and it's clear why expanding our Asian coverage was key to supporting our customers' growth."
About CardioMonitor.
Providing a globally consistent perspective enriched by local insights, CardioMonitor offers a complete view of practice and prescribing patterns for both primary care and specialty physicians across all cardiovascular, diabetes and anti-obesity agents. Based on 5,000 patient histories a year in the US and 4,500 in each major European and Asian market, CardioMonitor provides evidence-based decision support at the country and global levels, driving brand success across the life cycle, from pre-launch planning through expiration strategies.
About KantarHealth.
KantarHealth is the world's leading healthcare-focused global consultancy, specializing in portfolio optimization, market access, safety and outcomes, and brand and customer insights Formed by uniting Consumer Health Sciences, MattsonJack, TNS Healthcare and Ziment, it is the next-generation decision support partner to the pharmaceutical and biotech industries, delivering evidence-based guidance to support clients' global and local success. With 40+ offices throughout the Americas, Europe, Asia-Pacific, the Middle East and Africa, KantarHealth provides the broadest global footprint, coupled with the strongest local knowledge to help drive clients' maximum performance in every geography. Market-leading solutions ensure optimal decisions and actions across the brand life cycle, from assessing opportunities and sizing markets.to developing products and building access strategies.to positioning brands and creating messaging.to managing stakeholder relationships and monitoring treatment outcomes.
The KantarHealth logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4201
Contact Information.
To learn more about the expansion of CardioMonitor into Japan and China, contact Christine Brignall at +44 (0) 1372 825 913 or Christine.Brignall@kantarhealth.com For more information on KantarHealth, please contact Ilene Siegalovsky, Senior Vice President, Strategic Global Marketing, at Ilene.Siegalovsky@kantarhealth.com or 201-836-0040, ext. 225 or visit www.kantarhealth.com.